- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03608033
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
March 12, 2024 updated by: Omeros Corporation
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) assessed at 36 weeks from baseline.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 3, double-blind, randomized, placebo-controlled, study in patients aged 18 years and above with a biopsy-confirmed diagnosis of IgAN and with 24-hour UPE that is > 1 g/day.
The purpose of this study is to evaluate the efficacy and safety of narsoplimab (OMS721) compared to placebo on proteinuria and whether narsoplimab has the ability to slow disease progression in primary IgAN patients.
The primary objective of the study is to evaluate proteinuria reduction as assessed by 24-hour UPE at 36 weeks from baseline.
The trial will continue beyond 36 weeks in a blinded fashion to provide confirmatory evidence of long-term efficacy based on the annualized slope of eGFR over 24 months.
The trial will enroll approximately 450 patients with 225 patients per arm, all having biopsy-proven IgAN with eGFR≥30 mL/min/1.73m2
and 24 hour UPE >1g/day.
The study duration for each patient is expected to last approximately 112 weeks.
Study Type
Interventional
Enrollment (Actual)
356
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, C1280AEB
- Omeros Investigational Site
-
Cordoba, Argentina, X5016KEH
- Omeros Investigational Site
-
Salta, Argentina, 4400
- Omeros Investigational Site
-
-
Misiones
-
Posadas, Misiones, Argentina, 3300
- Omeros Investigational Site
-
-
-
-
Australian Capital Territory, Woden
-
Garran, Australian Capital Territory, Woden, Australia, 2606
- Omeros Investigational Site
-
-
Saint Albans
-
Footscray, Saint Albans, Australia, 3021
- Omeros Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Omeros Investigational Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Omeros Investigational Site
-
-
-
-
-
Gent, Belgium, 9000
- Omeros Investigational Site
-
Leuven, Belgium, 3000
- Omeros Investigational Site
-
Liège, Belgium, 1-4000
- Omeros Investigational Site
-
-
-
-
-
Plovdiv, Bulgaria, 4000
- Omeros Investigational Site
-
Plovdiv, Bulgaria, 4002
- Omeros Investigational Site
-
Sofia, Bulgaria, 1431
- Omeros Investigational Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z2M9
- Omeros Investigational Site
-
Vancouver, British Columbia, Canada, V6Z1Y6
- Omeros Investigational Site
-
-
Ontario
-
London, Ontario, Canada, N6A545
- Omeros Investigational Site
-
Toronto, Ontario, Canada, M5G2C4
- Omeros Investigational Site
-
-
-
-
Praha
-
Prague, Praha, Czechia, 128 08
- Omeros Investigational Site
-
-
-
-
-
Göttingen, Germany, 37075
- Omeros Investigational Site
-
Villingen-Schwenningen, Germany, 78052
- Omeros Investigational Site
-
-
Baden-Wrttemberg
-
Mannheim, Baden-Wrttemberg, Germany, 68167
- Omeros Investigational Site
-
-
Bayern
-
München, Bayern, Germany, 80336
- Omeros Investigational Site
-
-
Nordrhein-Westfalen
-
Aachen, Nordrhein-Westfalen, Germany, 52074
- Omeros Investigational Site
-
-
-
-
-
Athens, Greece, 11527
- Omeros Investigational Site
-
Heraklion, Greece, 71110
- Omeros Investigational Site
-
Iraklio, Greece, 71409
- Omeros Investigational Site
-
Patra, Greece, 26504
- Omeros Investigational Site
-
-
Pilea-Chortiatis
-
Thessaloniki, Pilea-Chortiatis, Greece, 57010
- Omeros Investigational Site
-
-
-
-
-
Baja, Hungary, H-6500
- Omeros Investigational Site
-
Budapest, Hungary, H-1097
- Omeros Investigational Site
-
Gyor, Hungary, H-9024
- Omeros Investigational Site
-
Pecs, Hungary, H-7624
- Omeros Investigational Site
-
Szeged, Hungary, 6720
- Omeros Investigational Site
-
-
-
-
-
Chandigarh, India, 160012
- Omeros Investigational Site
-
-
Ameerpet
-
Hyderabad, Ameerpet, India, 500038
- Omeros Investigational Site
-
-
Gujarat
-
Nadiad, Gujarat, India, 387001
- Omeros Investigational Site
-
-
Karnataka
-
Belagam, Karnataka, India, 590010
- Omeros Investigational Site
-
Mangalore, Karnataka, India, 575001
- Omeros Investigational Site
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Omeros Investigational Site
-
-
New India
-
New Delhi, New India, India, 110017
- Omeros Investigational Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302004
- Omeros Investigational Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500034
- Omeros Investigational Site
-
Hyderabad, Telangana, India, 500038
- Omeros Investigational Site
-
Hyderabad, Telangana, India, 500082
- Omeros Investigational Site
-
-
-
-
-
Bari, Italy, 70124
- Omeros Investigational Site
-
Bergamo, Italy, 24127
- Omeros Investigational Site
-
Eboli, Italy, 84025
- Omeros Investigational Site
-
Messina, Italy, 98125
- Omeros Investigational Site
-
Milano, Italy, 20122
- Omeros Investigational Site
-
Modena, Italy, 41124
- Omeros Investigational Site
-
Parma, Italy, 43126
- Omeros Investigational Site
-
Piacenza, Italy, 29121
- Omeros Investigational Site
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Omeros Investigational Site
-
Incheon, Korea, Republic of, 21431
- Omeros Investigational Site
-
Seoul, Korea, Republic of, 05278
- Omeros Investigational Site
-
Seoul, Korea, Republic of, 07061
- Omeros Investigational Site
-
Seoul, Korea, Republic of, 3080
- Omeros Investigational Site
-
Seoul, Korea, Republic of, 3722
- Omeros Investigational Site
-
-
Geyonggi-do
-
Seongnam, Geyonggi-do, Korea, Republic of, 13496
- Omeros Investigational Site
-
-
Gyeonggi-do
-
Anyang-si, Gyeonggi-do, Korea, Republic of, 14068
- Omeros Investigational Site
-
-
-
-
-
Kaunas, Lithuania, LT-50161
- Omeros Investigational Site
-
Vilnius, Lithuania, LT-08661
- Omeros Investigational Site
-
-
-
-
-
Krakow, Poland, 30-688
- Omeros Investigational Site
-
Olsztyn, Poland, 10-561
- Omeros Investigational Site
-
Warszawa, Poland, 04-749
- Omeros Investigational Site
-
-
Todzi
-
Łódź, Todzi, Poland, 92-213
- Omeros Investigational Site
-
-
-
-
-
Singapore, Singapore, 119074
- Omeros Investigational Site
-
Singapore, Singapore, 308433
- Omeros Investigational Site
-
-
-
-
-
Banská Bystrica, Slovakia, 97401
- Omeros Investigational Site
-
Kosice, Slovakia, 04011
- Omeros Investigational Site
-
-
-
-
-
Almeria, Spain, 04009
- Omeros Investigational Site
-
Barcelona, Spain, 08025
- Omeros Investigational Site
-
Cordoba, Spain, 14004
- Omeros Investigational Site
-
Lleida, Spain, 25198
- Omeros Investigational Site
-
Madrid, Spain, 28040
- Omeros Investigational Site
-
Madrid, Spain, 28041
- Omeros Investigational Site
-
Valencia, Spain, 46026
- Omeros Investigational Site
-
Zaragoza, Spain, 50009
- Omeros Investigational Site
-
-
San Sebastian De Lost Reyes
-
Madrid, San Sebastian De Lost Reyes, Spain, 28702
- Omeros Investigational Site
-
-
-
-
-
Stockholm, Sweden
- Omeros Investigational Site
-
-
-
-
-
Changhua City, Taiwan, 500
- Omeros Investigational Site
-
Hualien City, Taiwan, 97002
- Omeros Investigational Site
-
Kaohsiung City, Taiwan, 824
- Omeros Investigational Site
-
New Taipei City, Taiwan, 220
- Omeros Investigational Site
-
New Taipei City, Taiwan, 235
- Omeros Investigational Site
-
Taichung City, Taiwan
- Omeros Investigational Site
-
Taoyuan City, Taiwan, 333
- Omeros Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10300
- Omeros Investigational Site
-
Bangkok, Thailand, 10700
- Omeros Investigational Site
-
Chiang Mai, Thailand, 50200
- Omeros Investigational Site
-
Dusit, Thailand
- Omeros Investigational Site
-
Khon Kaen, Thailand, 40000
- Omeros Investigational Site
-
Songkla, Thailand, 90000
- Omeros Investigational Site
-
-
-
-
-
Ankara, Turkey, 06230
- Omeros Investigational Site
-
Bursa, Turkey, 16059
- Omeros Investigational Site
-
Edirne, Turkey, 22130
- Omeros Investigational Site
-
Istanbul, Turkey, 34899
- Omeros Investigational Site
-
Kocaeli, Turkey, 41380
- Omeros Investigational Site
-
Malatya, Turkey, 44200
- Omeros Investigational Site
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Omeros Investigational Site
-
Cardiff, United Kingdom, CF10 3XQ
- Omeros Investigational Site
-
Dartford, United Kingdom, DA2 8DA
- Omeros Investigational Site
-
London, United Kingdom, NW3 2QG
- Omeros Investigational Site
-
-
Evington
-
Leicester, Evington, United Kingdom, LE5 4PW
- Omeros Investigational Site
-
-
-
-
Alabama
-
Florence, Alabama, United States, 35630
- Omeros Investigational Site
-
-
Arizona
-
Mesa, Arizona, United States, 85206
- Omeros Investigational Site
-
Phoenix, Arizona, United States, 85016
- Omeros Investigation Sites
-
Scottsdale, Arizona, United States, 85258
- Omeros Investigational Site
-
Scottsdale, Arizona, United States, 85259
- Omeros Investigational Site
-
-
California
-
Los Angeles, California, United States, 90022-4302
- Omeros Investigational Site
-
Los Angeles, California, United States, 90025
- Omeros Investigational Site
-
Northridge, California, United States, 91324
- Omeros Investigational Site
-
San Dimas, California, United States, 91773
- Omeros Investigational Site
-
San Francisco, California, United States, 94118
- Omeros Investigational Site
-
Stanford, California, United States, 94304
- Omeros Investigational Site
-
Torrance, California, United States, 90509
- Omeros Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Omeros Investigational Site
-
-
Florida
-
Miami, Florida, United States, 33136
- Omeros Investigational Site
-
Miami Lakes, Florida, United States, 33014
- Omeros Investigational Site
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30046
- Omeros Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Omeros Investigational Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Omeros Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Omeros Investigational Site
-
Springfield, Massachusetts, United States, 01107
- Omeros Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- Omeros Investigational Site
-
Rochester, Minnesota, United States, 55905
- Omeros Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Omeros Investigational Site
-
-
New York
-
Fresh Meadows, New York, United States, 11365
- Omeros Investigational Site
-
New York, New York, United States, 10029
- Omeros Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Omeros Investigational Site
-
Columbus, Ohio, United States, 43210
- Omeros Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Omeros Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Omeros Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Omeros Investigational Site
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Omeros Investigational Site
-
Dallas, Texas, United States, 75246
- Omeros Investigational Site
-
Houston, Texas, United States, 77054
- Omeros Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Omeros Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or older at the onset of Screening
- Biopsy confirmed diagnosis of IgAN within 8 years prior to Screening
- Proteinuria of > 1 g/day within 6 months prior to Screening or uPCR > 0.75 by spot urine at Screening
- Mean of two proteinuria measurements > 1 g/day at baseline
- Estimated glomerular filtration rate of ≥ 30 mL/min/1.73 m² at Screening and baseline
Exclusion Criteria:
- Treatment with immunosuppressants (e.g., azathioprine or cyclophosphamide), or cytotoxic drugs, for IgA within 8 weeks prior to Screening. Treatment with immunosuppressants or cytotoxic drugs for IgAN is not allowed during the Run-In Period. Treatment with immunosuppressants are allowed if such treatment is for indications other than IgAN.
- Treatment with eculizumab within 8 weeks prior to Screening. Treatment with eculizumab is not allowed during the Run-In Period.
- Treatment with systemic corticosteroids within 8 weeks prior to Screening. Treatment with systemic corticosteroids is not allowed during the Run-In Period.
- Uncontrolled BP, a systolic BP of > 150 mmHg and a diastolic BP of > 100 mmHg at rest despite the combination of two or more anti-hypertensives including ACEIs, ARBs, or direct renin inhibitors at Screening and baseline
- Female patients who are pregnant, breast feeding, or planning to become pregnant up through 12 weeks after the last dose of study drug, including possible retreatments. Males who are planning to father children up through 12 weeks after the last dose of study drug, including possible retreatments
- Clinical or biological evidence of Type 1 diabetes mellitus (DM), or poorly controlled DM with hemoglobin A1c > 7.5 or with evidence of diabetic nephropathy on biopsy, systemic lupus erythematosus, IgA vasculitis (Henoch-Schonlein purpura), secondary IgAN, or other renal disease during Screening and Run-In
- History of renal transplantation
- Have a known hypersensitivity to any constituent of the investigational product
- Rapidly progressive glomerulonephritis
- Significant abnormalities in clinical laboratory values
- History of human immunodeficiency virus (HIV), evidence of immune suppression, active HCV infection (patients with positive anti-HCV antibody but a non-detected HCV RNA PCR can enroll), HBV infection (patients with positive HBsAg are excluded. For patients with isolated positive anti-HBc antibody, HBV DNA test by PCR must be non-detectable to enroll).
- Diagnosis of a malignancy except for adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or other cancer from which the patient has been disease-free for ≥ 5 years
- Have received any other investigational drug or device or experimental procedures and/or treatments within 30 days of the Screening Visit (SV)
- Initiation or change in dosing of sodium glucose co-transporter 2 inhibitors (SGLT2i) during Screening and Run-In Periods. However, a stable dose regimen established at least 8 weeks prior to screening is acceptable
- Treatment with Tarpeyo™ (budesonide) or other approved treatments for IgAN within 6 months prior to screening. Treatment with Tarpeyo is not allowed during Screening and Run-In Periods
- Treatment with Kerendia® (finerenone) within 6 months prior to screening. Treatment with Kerendia is not allowed during Screening and Run-In Periods
- Initiation of treatment with Filspari™ (sparsentan), a dual Endothelin Angiotensin Receptor Antagonist (dEARA) or similar medication within three months prior to screening. A stable dose initiated at minimum 3 months before screening is acceptable and will take the place of ACEi/ARB as background therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OMS721
Administration of OMS721
|
Biological: OMS721
|
Placebo Comparator: Placebo
Administration of Vehicle (D5W or Saline Solution)
|
5% Dextrose in water or normal saline solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in 24-hour UPE in IgA nephropathy (IgAN) patients assessed at 36 weeks from baseline
Time Frame: 36 Weeks
|
36 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal function as determined by the rate of change in eGFR at up to 96 weeks from baseline.
Time Frame: 96 Weeks
|
96 Weeks
|
|
Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 weeks and 48 weeks
Time Frame: 36 and 48 Weeks
|
36 and 48 Weeks
|
|
Time-averaged change from baseline in the log-transformed 24-hour UPE between 36 and 72 weeks
Time Frame: 36 and 72 Weeks
|
36 and 72 Weeks
|
|
Safety and tolerability of narsoplimab for the treatment of IgAN
Time Frame: Week 112
|
As assessed by the incidence of adverse events through study completion (Week 112) in the patient group with baseline 24-hour UPE ≥ 2 g and in the all-patients population
|
Week 112
|
Pharmacokinetics of narsoplimab intravenous infusion
Time Frame: Week 12
|
By evaluating the maximum concentration (Cmax) parameters at baseline and study days, T1, T4, T8, T10, T12 population (24-hour UPE > 1 g/day)
|
Week 12
|
Assessment of pharmacokinetics of narsoplimab intravenous infusion
Time Frame: Week 12
|
By evaluating the area under the concentration-time curve from dosing time (AUC) at baseline and study days, T1, T4, T8, T10,T12
|
Week 12
|
Pharmacokinetics of narsoplimab intravenous infusion
Time Frame: Week 12
|
Pharmacokinetics of narsoplimab intravenous infusion by evaluating the maximum concentration Cmax parameters at baseline and study days, T1 Weeks 1, T4 Week 2-11, T8 Week 2-11, T10 Week 2-11, T12 Week 12 ±2 days measurement of anti-drug antibodies and neutralizing antibodies at baseline and study days T1, T4, T8, T10, T12
|
Week 12
|
Assessment of pharmacodynamics of narsoplimab intravenous infusion
Time Frame: Week 12
|
Assessment of pharmacokinetics of narsoplimab intravenous infusion by evaluating the area under the concentration-time curve from dosing time AUC at baseline and study days, T1 Weeks 1, T4 Week 2-11, T8 Week 2-11, T10 Week 2-11, T12 Week 12 ±2 days
|
Week 12
|
Assessment of pharmacodynamics of narsoplimab intravenous infusion with presence of positive anti-drug antibodies
Time Frame: Week 12
|
Assessment of percentage of participants with presence of positive anti-drug antibodies following intravenous infusion of narsoplimab at baseline and study days T1 Weeks 1, T4 Week 2-11, T8 Week 2-11, T10 Week 2-11, T12 Week 12 ±2 days.
|
Week 12
|
Assessment of percentage of participants with presence of neutralizing antibodies
Time Frame: Week 12
|
Assessment of percentage of participants with presence of neutralizing antibodies following intravenous infusion of narsoplimab at baseline and study days T1 Weeks 1, T4 Week 2-11, T8 Week 2-11, T10 Week 2-11, T12 Week 12 ±2 days.
|
Week 12
|
Change from baseline in log-transformed 24-hour uPCR through 36 weeks.
Time Frame: Week 36
|
Week 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 16, 2018
Primary Completion (Actual)
October 16, 2023
Study Completion (Actual)
October 18, 2023
Study Registration Dates
First Submitted
June 21, 2018
First Submitted That Met QC Criteria
July 23, 2018
First Posted (Actual)
July 31, 2018
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMS721-IGA-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IgA Nephropathy
-
Josep M CruzadoWyeth is now a wholly owned subsidiary of PfizerCompletedGlomerulonephritis, IGA | IGA Nephropathy | Nephropathy, IGASpain
-
Visterra, Inc.CompletedImmunoglobulin A Nephropathy | IgA Nephropathy | IgAN - IgA NephropathyUnited States
-
Rigel PharmaceuticalsCompletedIGA NephropathyUnited States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
-
Uppsala University HospitalHaukeland University Hospital; University Hospital, Linkoeping; Smerud Medical...UnknownIGA NephropathyNorway, Sweden
-
Calliditas Therapeutics ABArchimedes Development LtdCompletedIGA NephropathySweden
-
Sun Yat-sen UniversityUnknownIGA NephropathyChina
-
Guangdong Provincial People's HospitalCompletedGlomerulonephritis | IGA NephropathyChina
-
Nanjing University School of MedicineCompleted
-
Rigel PharmaceuticalsWithdrawn
-
Zhi-Hong Liu, M.D.Completed
Clinical Trials on OMS721
-
Omeros CorporationUnknownThrombotic Microangiopathies | Atypical Hemolytic Uremic SyndromeUnited States
-
Omeros CorporationImpatients N.V. trading as myTomorrowsAvailableHematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
-
Omeros CorporationCompletedThrombotic MicroangiopathiesUnited States, Belgium, Bulgaria, Hong Kong, Italy, Lithuania, Malaysia, New Zealand, Poland, Singapore, Taiwan, Thailand
-
Michal NowickiAvailableThrombotic Microangiopathy
-
Omeros CorporationUnknownLupus Nephritis | IgAN | C3 Glomerulopathy | MNUnited States, Hong Kong
-
QuantumLeap Healthcare CollaborativeM.D. Anderson Cancer Center; University of Colorado, Denver; University of Pennsylvania and other collaboratorsRecruitingCOVID-19United States